Abiopharma

New Form 8-K - NovoCure Ltd Filed: 2025-08-28 AccNo: 0001645113-25-000032 Size: 140 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Compugen - Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

MindMed to Participate in September Investor Conferences

Cibus Enters into Agreement with the Latin American Rice Hybrid Consortium to Provide Cibus’ Herbicide Tolerance Trait

Passage Bio, Inc. - Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025